Unknown

Dataset Information

0

Effects of Repaglinide Versus Glimepiride on 1,5-Anhydroglucutol and Glycated Hemoglobin Levels in Japanese Patients With Type 2 Diabetes.


ABSTRACT: Background:Postprandial hyperglycemia is a well-known risk factor for cardiovascular disease. We prospectively examined the effects of repaglinide on postprandial hyperglycemia in patients with type 2 diabetes. Methods:During this 24-week, single-arm, prospective study, we enrolled 10 patients with type 2 diabetes who were previously being administered glimepiride (0.5 or 1 mg/day) and switched it with repaglinide (0.75 or 1.5 mg/day). Changes in their metabolic parameters were evaluated at the end of the study period. Results:After replacing glimepiride with repaglinide, increases were observed in 1,5-anhydroglucitol levels (baseline, 5.46 ± 1.96 versus 24 weeks, 9.15 ± 4.48 µg/mL, P = 0.004) but not in glycated hemoglobin levels (baseline, 7.7 ± 0.5 versus 24 weeks, 7.4 ± 0.6%, P = 0.100). Body weight remained unchanged. Conclusion:Compared with glimepiride, repaglinide improved 1,5-anhydroglucitol levels but had no effect on glycated hemoglobin. This suggests that repaglinide is a useful option for treating postprandial hyperglycemia.

SUBMITTER: Yamada H 

PROVIDER: S-EPMC6188029 | biostudies-other | 2018 Nov

REPOSITORIES: biostudies-other

altmetric image

Publications

Effects of Repaglinide Versus Glimepiride on 1,5-Anhydroglucutol and Glycated Hemoglobin Levels in Japanese Patients With Type 2 Diabetes.

Yamada Hodaka H   Kakei Masafumi M   Hara Kazuo K  

Journal of clinical medicine research 20181009 11


<h4>Background</h4>Postprandial hyperglycemia is a well-known risk factor for cardiovascular disease. We prospectively examined the effects of repaglinide on postprandial hyperglycemia in patients with type 2 diabetes.<h4>Methods</h4>During this 24-week, single-arm, prospective study, we enrolled 10 patients with type 2 diabetes who were previously being administered glimepiride (0.5 or 1 mg/day) and switched it with repaglinide (0.75 or 1.5 mg/day). Changes in their metabolic parameters were ev  ...[more]

Similar Datasets

| S-EPMC5860385 | biostudies-literature
| S-EPMC8566134 | biostudies-literature
| S-EPMC6425874 | biostudies-literature
| S-EPMC5841997 | biostudies-literature
| S-EPMC6123036 | biostudies-literature
| S-EPMC8055886 | biostudies-literature
| S-EPMC6447341 | biostudies-literature
| S-EPMC8015815 | biostudies-literature
| S-EPMC2809278 | biostudies-literature
| S-EPMC4592895 | biostudies-literature